WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 11, Issue 17, 655-668. Review Article ISSN 2277– 7105

A REVIEW ARTICLE ON ANTICANCER AGENTSFROM VARIOUS SOURCES

***Farheen A. Shah, Shailaja W. Gawande, Dr. Manisha D. Kitukale**

P. Wadhwani College of Pharmacy, Yavatmal- 445001 Maharashtra, India.

Article Received on
01 November 2022,
Revised on 22 Nov. 2022,
Accepted on 12 Dec. 2022
DOI: 10.20959/wjpr202217-26574

***Corresponding Author**
Farheen A. Shah
P. Wadhwani College of Pharmacy, Yavatmal-445001 Maharashtra, India.

ABSTRACT

Natural merchandise have afforded a chic supply of compounds that have found several applications within the fields of drugs, pharmacy and biology. at intervals the sphere of cancer, variety of vital new commercial medication are obtained from natural sources, by structural modification of natural compounds, or by the synthesis of latest compounds, designed following a natural compound as model. The seek for improved cytotoxic agents continues to be a crucial line within the discovery of recent antitumour medication. the massive structural diversity of natural compounds and their bioactivity potential have meant that many merchandise isolated from plants, marine flora and microorganisms will function "lead" compounds for improvement of their therapeutic potential by molecular modification. to boot, semisynthesis processes of latest compounds, obtained by molecular modification of the practical teams of lead compounds, ar able to generate structural analogues with bigger medicine activity and with fewer facet effects. These processes, complemented with high-throughput screening protocols, combinatorial chemistry, procedure chemistry and bioinformatics ar able to afford compounds that ar much more economical than those presently utilized in clinical observe. Combinatorial biogenesis is additionally applied for the modification of natural microbic merchandise. Likewise, advances in genetics and also the advent of biotechnology have improved each the invention and production of latest natural compounds.

KEYWORDS: Earthly plants, Microorganisms, Endophytic fungi.

INTRODUCTION

Plants have an extended history of use within the treatment of cancer (Hartwell, 1982). In his review, Hartwell lists over 3000 plant species that have reportedly been employed in the

treatment of cancer, however in several instances, the "cancer" is indefinable, or reference is created to conditions like "hard swellings", abscesses, calluses, corns, warts, polyps, or tumors, to call a couple of. Such symptoms would typically apply to skin, "tangible", or visible conditions, and will so typically correspond to a cancerous condition, however several of the claims for effectualness ought to be viewed with some skepticism as a result of cancer, as a particular illness entity, is probably going to be poorly outlined in terms of lore and ancient medication. this isoften in distinction to alternative plant-based therapies employed in ancient medication for the treatment of afflictions like protozoal infection and pain, that square measure a lot of simply outlined.

Wherever the diseases square measure usually rife within the regions wherever ancient medication systems square measure extensively used. notwithstanding, despite these observations, plants have vie a very important role as a supply of effective anti-cancer agents, and it's important that over hr of presently used anti- cancer agents square measure derived in a method or another from natural sources, together with plants, marine organisms and micro-organisms (Cragg et al., 2005, Newman et al., 2003).

The explore for anti-cancer agents from plant sources started in earnest within the Fifties with the invention and development of the dicot genus alkaloids, Velban and periwinkle plant derivative, and also the isolation of the cytotoxic podophyllotoxins. As a result, the us National Cancer Institute (NCI) initiated an in depth plant assortment program in 1960, targeted chiefly in temperate regions. This diode to the invention of the many novel chemotypes showing a spread of cytotoxic activities (Cassady and Douros, 1980), together with the taxanes and camptothecins, however their development into clinically active agents spanned a amount of some thirty years, from the first Nineteen Sixties to the Nineteen Nineties. This plant assortment program was terminated in 1982, however the event of recent screening technologies diode to the revival of collections of plants and alternative organisms in 1986, with attention on the tropical and sub-tropical regions of the planet. it's attention-grabbing to notice, but that no new plant-derived clinical anti-cancer agents have, as yet, reached the stage of general use, however variety of agents square measure in presymptomatic development.

MATERIALS AND METHODS

1) Earthly plants as a source of anticancer agents

Herbal treatments ar the most widespread sort of ancient medication, and ar extremely

profitable within the international marketplace. The international market for flavorer merchandise is expected to succeed in $5 trillion by 2050.[1] Plants manufacture a massive diversity of bioactive secondary metabolites that have a long history of use in the treatment of cancer. In our recent review on the role of plants in malignant neoplasm drug discovery[2] we tend to created AN intensive effort to discuss the necessary role of plant derived merchandise in the development of many clinically helpful anti-cancer agents. The era of the use of plant primarily based natural merchandise as malignant neoplasm agents was introduced by the historical office Natural Product Communications 2014 Vol. 9 No. eleven 1655 – 1669 isolation of 2 alkaloidsVinblastine and periwinkle plant derivative from the Madagascarperiwinkle, Catharanthus roseus G. Don (Apocynaceae).

These were followed by a series of various alternative malignant neoplasm agents such as camptothecin (a quinoline organic compound isolated from Camptotheca acuminate), Phodophyllotoxin (obtained from magnoliid dicot genus peltatum), paclitaxel (isolated from the bark of the Pacific yew (Taxusbrevifolia Nutt)and a range of their semi-synthetic analogues, like topotecan, irinotecan, docetaxel, cabizetaxel, etoposide, teniposideetc.[2]



Figure 1: Graphical Abstract.

2) Microorganisms as a source of anticancer agents

Microorganisms square measure a plentiful supply of structurally numerous bioactive substances, and have provided vital contributions to the discovery of medicament agents. The success of many medicative medicine from microbic origin such as penicillins (from fungus genus species), cephalosporins (from Cephalosporium acremonium), cyclosporine (from Trichoderma and Tolypocladiumspecies), penicillin (from fungus genus griseofulvum

fungus), mevastatin (compactin; from fungus genus species) and lipid-lowering medication (from genus Aspergillus species); ivermectins (from actinomycete species) and β- lactam antibiotics from varied fungous taxa, has shifted the focus of drug discovery from plants to microorganisms.[3] 5 categories of being (cyanophytes, marine microbes, extremophiles, microbic symbionts and plant endophytes) square measure currently famous to turn out a massive selection of secondary metabolites against abnormal environments and for protection.[4-8]

Micro-organisms square measure a prolific supply of structurally numerous bioactive metabolites and have yielded some of the most vital product of the pharmaceutical trade. Secondary metabolites from microorganisms with potential anti-tumor activities have been discovered in recent years. antitumour antibiotics square measure among the most vital of the approved microbic derived antitumor medicine embrace everolimus (RAD-001, 1). It is a 40-O-(2-hydroxyethyl) spinoff of a macrolide, sirolimus (2) isolated from actinomycete hygroscopicus[9] acts as AN substance of the class target of rapamycin (mTOR) and marketed below the brand Afinitor by Novartis. it absolutely was approved by bureau in might 2011 for the treatment of advanced duct gland system tumours. Then in Gregorian calendar month 2012, it was approved by bureau for the treatment of urinary organ angiomyolypoma with stem induration advanced, and in July 2012 was approved for the treatment of secretion receptor-positive, HER2-negative breast cancer. Carfilzomib (CFZ, tradename Kyprolis, 3) is a tetrapeptideepoxy-ketone and a selective proteasome substance. The U.S. bureau approved its use on twenty July 2012 for relapsed and refractory multiple malignant tumor patients United Nations agency have received at least 2 previous therapies, together with bortezomib ANd an immunomodulatory agent. It is AN analog of epoxomicin(4), a potent ANti-tumor agent isolated from an unidentified Actinomycetes strain, No Q996-17.[10]

It is used as a selective and irreversible substance of the 20S proteasome and is marketed by calcedony prescription drugs. At gift microorganisms square measure thought-about as the most promising sources of natural anti-tumor medicine attributable to their wide distribution and diversity among all organisms on earth. in addition, microorganisms that will survive in abnormal environments secrete metabolites of potential medical applications. AN exciting "pipeline" of new antitumor clinical and presymptomatic agents have emerged from intense efforts over the past decade to a lot of effectively explore the made chemical diversity offered by the micro-organisms. To date, the majority of the antitumor medicine square measure

developed either from plants or bacterium however no fungous metabolites or their derivatives have been approved as antitumor medicine. fungous metabolites and derivatives therefrom square measure abundant less investigated for their potential in cancer medical care however last decade has shown a wonderful increase within the variety of antitumor fungous derived compounds in the clinical pipeline. Fungi square measure famous for manufacturing several novel metabolites showing a large vary of various bioactivities with an outsized variety reportable to possess cytotoxic properties.[11-18]

over 1500 fungous metabolites had been reportable to show anti-tumor and antibiotic activity. Some of them have entered clinical trials whereas others function lead structures within the rummage around for clinically applicable antitumour medicine.[19] over half-hour of isolated metabolites from fungi square measure from genus Aspergillus and fungus genus spp.[20] One of the best evaluated fungous metabolites in the antitumor space is fumagillin (5) that arises from a mixed sesquiterpenoid (C15-nucleus) and polyketide (C10 aspect chain) synthesis of the flora genus Aspergillus fumigatus.[21] several semi-synthetic analogues of fumagillin are synthesized so as to extend efficiency and at the same time decrease toxicity. The most potent of these includes TNP-470 (6) and CKD-732 (7). TNP-470 has been shown to inhibit development in vitro and in vivo. In 1992, TNP-470 entered clinical development for cancer as AN anti-angiogenic agent for the treatment of breast, prostate, and brain cancer, as well as Kaposi cancer.[22] TNP-470 scrawny the expansion of each malignancy it touched- animal tumours, human tumours, and spreading tumours. It suppressed tumours of the ovaries, colon, prostate, and breasts. In some cases the tumours shrank; in others, they disappeared.[23] but some patients, whose malignancies were inhibited, or even eliminated, started showing unacceptable aspect effects - issues with motor coordination, seizures, and unease.[24]

CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] has additionally entered clinical trials, being even less attackable and fewer toxicant than TNP-470.[25-27] phase I clinical trials were done to judge the protection, tolerability, and pharmacology (PK) of CKD-732 in combination with capecitabine and oxaliplatin (XELOX) in 9 pathological process large intestine cancer patients United Nations agency had progressed on irinotecan-based therapy. The section II trials suggested dose of CKD-732 was determined to be five mg/m2/d, and this dose was safely combined with typical doses of capecitabine and oxaliplatin in this patient population. more studies on the effects of CKD-732 in combination with xelox and alternative chemotherapies employing a larger study

population square measure secured.[28] Another antitumor lead compound of fungous origin is the sesquiterpene illudin S (8), 1st isolated from the fungus Omphalotusilludens.[29] several semi-synthetic analogues of illudin S are synthesized, the foremost promising of that is that the alkylating agent irofulven (9). Irofulven incorporates a considerably superior therapeutic index in comparison to the parent natural product showing a lot of by selection towards human neoplasm cells.[30] In 2001, the bureau granted quick track standing to the novel anti-tumor drug-candidate irofulven (also famous as hydroxymethylacylfulvene, HMAF, and MGI-114). It is a DNA-alkylating agent that has AN uncommon mechanism. In section I and phase II clinical trials, conducted by MGI pharmaceutical company and therefore the National Cancer Institute, irofulven exhibited notably promising results in shrinking malignant solid tumours, together with those of drug-resistant cancers.[31] It incontestible outstanding results on patients with duct gland cancer that had stopped responding to medicine, giving new hope for patients with this deadly malady. primarily based on these favorable results, a section III clinical trial of irofulven for the treatment of duct gland cancer was started.[32] what is more, a multi- center section II trial was conducted by the medicine medicine cluster to judge the activity and safety of irofulven in patients with perennial animal tissue sex gland cancer.[33] Plinabulin (NPI-2358, 10), another compound of fungous origin, was isolated from cultures of the marine-derived flora genus Aspergillus ustus.[34]



Figure 2: Classification of commonly used chemotherapeutics depending on their mechanism of action.[35-37]

3) Endophytic fungi as a source of anticancer agents

Endophytes refer to the fungi, yeast and bacterium that live within plant tissue for at least half of their life cycle while not inflicting any malady symptoms within the host.[38] it's been calculable that there could be as several as one million totally different endophytic plant life taxa.[19] The asymptomatic nature of endophyte occupation in plant tissue has prompted a focus on dependent or mutualistic relationships betweenendophytes and their hosts.[39-40] In comparison to plant life plant pathogens and plant life soil isolates, comparatively few secondary metabolites have been isolated from endophytic fungi. These secondary metabolites of endophytic origin ar synthesized via numerous metabolic pathways and belong to various structural teams, i.e., xanthones, steroids, isocumarines, phenols, quinones, furandiones, terpenoids, depsipeptides, and cytochalasines. The majority of the antitumour medication like taxol, camptothecin, magnoliopsid genus alkaloids, and podophylotoxin ar from plant origin, as a result.

The assortment of plants from the wild for extraction of natural merchandise has rendered some of the necessary plant species to become either vulnerable or critically vulnerable or perhaps extinct. On the different hand high costs of these antitumour merchandise in the clinical market have light-emitting diode to a widespread analysis interest around the globe, to develop various sources/routes for the assembly of those compounds. It was in 1993, once taxol was discovered to be made in a recently represented plant life living in the yew tree.[41] Since, then it has been found during a variety of different endophytic fungi, gap the likelihood of taxol production by culturing one of these plant life species and therefore reducing time and price for production of the compound.[42-43] Paclitaxel will therefore be thought-about as the 1st cytotoxic plant life secondary substance in clinical use. The endophytic plant life Entrophospora infrequens obtained from Nothapodytes foetida was 1st according to have the ability to manufacture camptothecin (CPT). It produces CPT, 9-methoxycamptothecin[40], and 10- hydroxycamptothecin.[41]

Compounds forty and forty one ar 2 necessary analogues of CPT with lower toxicity and potential antitumour efficaciousness.[44] Another part known plantlife (RJMEF001) happiness to the family of Phycomycetes group, isolated from the inner bark of N. foetida, growing in India, has been according to manufacture CPT.[45] In addition, studies on C. roseus endophytes discovered that Alternaria sp. and Fusarium oxysporum were isolated from vascular tissue of the plant material and were accountable for production of magnoliopsid

genus alkaloids.[46] equally the aryltetralignan podophyllotoxin has been according to be made by endophytes, particularly Phialocephela fortinii, isolated from the rhizomes of the host plant Podophyllum peltatum.[47] Trametes shock- headed, associate endophyte of P. hexandrum was according to manufacture podophylotoxin. It has been according that the active compounds made by endophytes have structure varieties that ar way on the far side those made by their host plants. therefore improvement of existing medication by modifying them with endophytes is wonderful means of exploiting novel metabolites.



Figure 3: Mechanisms of chemotherapeutic drug resistance in cancer cells.[48-52]

DISCUSSION

Anticancer drug, conjointly referred to as cancer drug, any drug that's effective within the treatment of malignant, or cancerous, disease. There ar many major categories of antitumor drugs; these embrace alkylating agents, antimetabolites, natural merchandise, and hormones. additionally, there ar variety of medicine that don't fall at intervals those categories however thatdemonstrate antitumor activity and so ar employed in the treatment of malignant illness. The term therapy ofttimes is equated with theutilization of antitumor medicine, though it additional accurately refers to the utilization of chemical compounds to treat illness typically. One of the primary medicine that was used clinically in fashionable medication for the treatment of cancer was the alkylating agent mechlorethamine, a chemical compound that within the Forties was found to be effective in treating lymphomas. In 1956 the cancer drug immunosuppressive drug became the primary drug to cure a solid neoplasm, and therefore the following year 5-fluorouracil was introduced because the initial of a brand new category of tumour-fighting compounds called pyrimidine analogs. Since then several antitumor medicine are developed and used with a lot of success. The decision to use a particular

antitumor drug depends on several factors, together with the sort and placement of the cancer, its severity, whether or not surgery or radiotherapy will or ought to be used, and therefore the facet effects related to the drug. Most antitumor medicine ar administered intravenously; but, some is taken orally, et al. is injected intramuscularly or intrathecally (within the spinal cord). The treatment of cancer is sophisticated therein the medicine used target human cells, albeit cells that have undergone genetic changes and ar dividing at a quick and uncontrolled rate. However, sure antitumor medicine will differentiate to a point between traditional tissue cells and cancer cells, and therefore the rate at that cancer cells proliferate might really play a task within the apparent property of agents. as an example, alkylating agents, that act on cells in any respect stages of the cell cycle, seem to be most hepatotoxic to cells within the synthesis, or S, stage, once deoxyribonucleic acid is within the method of replicating associated unmated nucleotides (the nitrogen-containing units of deoxyribonucleic acid and RNA) ar most susceptible to groupation (the addition of an alkyl group). within the late twentieth and early twenty first centuries, the identification of molecular options distinctive to cancer cells oxyacetylene the event of targeted cancer therapies, that possess a comparatively high degree of specificity for cancer cells. The specificity of antitumor medicine plays a very important role in reducing the severity of facet effects related to the drugs' use. Indeed, as a result of cancer cells ar like traditional human cells, antitumor agents ar typically hepatotoxic to traditional cells and might cause varied facet effects, a number of that ar grave. Such facet effects embrace hair loss, sores within the mouth and on alternative secretion membranes, internal organ anomalies, bone marrow toxicity, and severe nausea and regurgitation. The bone marrow toxicities end in anemia in addition as in weakened resistance to infectious agents. Permanent sterility also can result. Those adverse effects might need that the drug dose be reduced or the drug plan be modified to create the drug tolerable to the patient. In rare instances prolonged use of antitumor medicine will cause the event of secondary cancers. the sort of agent, the first cancer that it's wont to treat, and therefore the total accumulative dose administered influence the extent to that associate antitumor drug is cancer (cancer-causing). ofttimes occurring secondary cancers related to antitumor drug medical aid ar myelodysplastic syndrome and acute leukemias, risk of that is accumulated notably with the utilization of alkylating agents and topoisomerase inhibitors.[53]

CONCLUSION

A arrange for the diagnosis and treatment of cancer could be a key part of any overall cancer management plan. Its main goal is to cure cancer patients or prolong their life

significantly, making certain a decent quality of life. so as for a identification and treatment programme to be effective, it mustn't ever be developed in isolation.

It has to be coupled to associate degree early detection programme in order that cases square measure detected at associate degree early stage, once treatmentis simpler and there's a larger likelihood of cure. It additionally has to be integrated with a palliative care programme, in order that patients with advanced cancers, World Health Organization will now not get pleasure from treatment, can get adequate relief from their physical, psychosocial and non secular suffering. what is more, programmes ought to embrace a awareness-raising part, to coach patients, family and community members concerning the cancer risk factors and therefore the want for taking preventive measures to avoid developing cancer.

Where resources square measure restricted, identification and treatment services ought to at first target all patients presenting with curable cancers, like breast, cervical and oral cancers that may be detected early. they may additionally embrace childhood acute bodily fluid cancer, that features a high potential for cure though it can't be detected early. Above all, services ought to be provided in associate degree evenhanded and property manner. As and once additional resources become obtainable, the programme will be extended to incorporate alternative curable willcers moreover as cancers that treatment can prolong survival significantly.

REFERENCES

1. Anand C, Neetu S. (2011) Contribution of world health organization in the global acceptance of Ayurveda. Journal of Ayurveda Integrative Medicine, 2: 179–186.
2. Khazir J, Mir BA, Pilcher L, Riley DL. (2014) Role of plants in anticancer drug discovery. Phytochemistry letters, 7: 173-181.
3. Sources of Drug Discovery. http://medicinalchemistryproject. info/ Discovery.html
4. Pearson L, Mihali T, Moffitt M, Kellmann R, Neilan B. (2010) On the chemistry, toxicology and genetics of the cyanobacterial toxins, microcystin, nodularin, saxitoxinand cylindrospermopsin.Marine Drugs, 8: 1650–1680.
5. Jensen PR, Williams PG, Oh DC, Zeigler L, Fenical W. (2007) Species- specific secondary metabolite production in marine actinomycetes of the genus Salinispora. Applied Environmental Microbiology, 73: 1146–1152.

6. Thornburg CC, Zabriskie TM, McPhail KL. (2010) Deep-sea hydrothermal vents: potential hot spots for natural products discovery. Journal of Natural Products, 73: 489–499.
7. Fujiwara S. (2002) Extremophiles: developments of their special functions and potential resources. Journal of Biosciences and Bioengineering, 94: 518–525.
8. Kroiss J, Kaltenpoth M, Schneider B, Schwinger MG, Hertweck C, Maddula RK, Strohm E, Svatos A. (2010) Symbiotic Streptomycetes provide antibiotic combinationprophylaxis for wasp offspring. Natural Chemical Biology, 6: 261–263.
9. Vézina C, Kudelski A, Sehgal SN. (1975). "Rapamycin (AY-22,989), a new antifungal antibiotic". Journal of Antibiotic, 28: 721–6
10. Lihao M, Royce M, Benjamin HBK, Mikael E, Ny S, Craig MC. (1999) Epoxomicin, a potent and selectiveproteasome inhibitor, exhibits in vivo antiinflammatory activity. Proceedings of the National Academy of Science USA, 96: 10403-10408..
11. Bode HB, Bethe B, Höfs R, Zeek A. (2002) Big effects from small changes: possible ways to explore nature's chemical diversity. Chemistry and Chemical Biology, 3: 619–627.
12. Chin YW, Balunas MJ, Chai HB. (2006) Drug discovery from natural sources. The AAPS Journal, 8: 239–253.
13. Donadio S, Monicardini P, Alduina R, Mazzaa P, Chiocchini C, Cavaletti L, Sosio M, Puglia AM. (2002) Microbial technologies for the discovery of novel bioactive metabolites. Journal of Biotechnology, 99: 187-198.
14. Gunatilaka AAL. (2006) Natural products from plant-associated microorganisms: Distribution, structural diversity, bioactivity, and implications of their occurrence. Journal of Natural Products, 69: 509–526.
15. Mitchell AM, Strobel GA, Hess WM, Vargas PN, Ezra D. (2008) Muscodorcrispans, a novel endophyte from Anansananassoides in the Bolivian Amazon, Fungal Diversity, 31: 37-43.
16. Kock JLF, Strauss T, Pohl CH, Smith DP, Botes PJ, Pretorius EE, Tepeny T, Sebolai O, Botha A, Nigam S. (2001) Bioprospecting for novel oxylipins in fungi: the presence of 3-hydroxy oxylipins in Pilobolus. Antonie van Leeuwenhoek, 80: 93–99.
17. Misiek M, Hoffmeister D. (2007) Fungal genetics, genomics, and secondary metabolites in pharmaceutical sciences. Planta Medica, 73: 103-115.
18. Schneider P, Misiek M, Hoffmeister D. (2008) In vivo and in vitro production options for fungal secondary metabolites. Molecular Pharmacology, 5: 234-242.

19. Selim KA, El-Beih AA, AbdEl-Rahman TM2, El-Diwany AI. (2012)Biology of endophytic fungi. Current Research in Environmental and Applied Mycology, 2: 84-97.
20. Saleem M, Ali MS, Hussain S, Jabbar A, Ashraf M, Lee YS. (2007) Marine natural products of fungal origin. Natural Product Reports, 24: 1142-1152.
21. Birch AJ, Hussain SF. (1969) Studies in relation to biosynthesis. Part XXXVIII. A preliminary study of fumagillin. Journal of Chemical Society(C), 1473–1474.
22. Kruger EA, Figg WD. (2000) TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opinion in Investigational Drugs, 9: 1383-1396.
23. Bernsen HJJA, Rijken PFJW, Peters H, Bakker H, van der Kogel AJ.(1998)The effect of the anti-angiogenic agent TNP-470 on tumor growth, vascular area, vascular density and tumor perfusion of two different subcutaneously implanted human glioma xenografts (E98 and E106) in nude mice. Journal of Neuro Oncolology, 38: 51-57.
24. Angiogenesis backgrounder. http://www.news. harvard.edu/gazette/2004/02.26/01-tnp.html.
25. Sang J S, Hei-Cheu J, Joong BA, Sun YR, Jae KR, Kyung SP, Dal-Hyun K, Chin K, Hyun CC. (2010) A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Investigational New Drugs, 28: 650-658.
26. Kim EJ, Shin WH. (2005) General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. Biological and Pharmaceutical Bulletin, 28: 217-223.
27. Lee HS,Choi WK, Son HJ, Lee SS, Kim JK, Ahn SK, Hong CI, Min HK, Kim M, Myung SW. (2004) Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. Archives of Pharmacal Research, 27: 265-272.
28. Shin SJ, Ahn JB, Park KS, Lee YJ, Hong YS, Kim TW, Kim HR, Rha SY, Roh JK, Kim DH, Kim C, Chung HC. (2012) A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Investigational New Drugs, 30: 672- 680.
29. Thomas G, Paul A K, Kay CP, Laura KC, Gary M. (1996) MIsolation of IlludinS from the Mature Basidiocarp of Omphalotus Illudens, and Isolation of IlludinsS and M from the Fermentation Broth of Omphalotus Olearis. Natural Product Letters, 9: 87-95.
30. Hendrik G, Ietidal E M, Alexander P, Stefan K, Harald G, Gabriele MK. (2010) Fungal

metabolites: structural diversity as incentivefor anticancer drug development. Phytochemistry Reviews, 9: 537–545.

31. Wang Y, Wiltshire T, Senft J, Wenger SL, Reed E, Wang W. (2006) Fanconianemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Molecular Cancer Therapeutics, 5: 3153-3161.
32. Elinoar S. (2008) Irofulven – Halloween Trick or a Beacon of Light. Medicinal mushrooms, Volume 1: 1.
33. Russell J S, John AB, Mark SS, David S.M, Krishnansu ST, Carolyn YM, David W, McMeekin DS, Jacob R. (2010) A phase II evaluation of Irofulven (IND#55804, NSC#683863) as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group trial. International Journal of Gynecological Cancer, 20: 1137–1141.
34. Kanoh K, Kohno S, Asari T, Harada T, Katada J, Muramatsu M, Kawashima H, Sekiya H. (1997) Uno, I. (-)-Phenylahistin: a new mammalian cell cycle inhibitor produced by Aspergillus ustus. Bioorganic and Medicinal Chemistry Letters, 7: 2847–2852.
35. Le, T.; Bhushan, V.; Sochat, M.; Chavda, Y. First Aid for the USMLE Step 1, 1st ed.; McGraw-Hill Education: New York, NY, USA, 2017; pp. 416–419. [Google Scholar]
36. Nussbaumer, S.; Bonnabry, P.; Veuthey, J.L.; Fleury-Souverain, S. Analysis of anticancer drugs: A review. Talanta 2011, 85, 2265–2289. [Google Scholar] [CrossRef]
37. Luqmani, Y.A. Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract, 2005; 14: 35–48. [Google Scholar] [CrossRef]
38. Chandra S, Bandopadhyay R, Kumar V, Chandra R. (2010) Acclimatization of tissue cultured plantlets: from laboratory to land. Biotechnology Letters, 32: 1191–1205.
39. Firáková S, Šturdíková M, Múčková M. (2007) Bioactive secondary metabolitesproduced by microorganisms associated with plants. Biologia, 62: 251–257.
40. Limsuwan S, Trip EN, Kouwenc TRHM, Piersmac S, Hiranrat A, Mahabusarakam W, Voravuthikunchai SP, Van Dijl JM, Kayser O. (2009) A new candidate as natural antibacterial drug from Rhodomyrtustomentosa. Phytomedicine, 16: 645–651.
41. Stierle AA, Strobel G, Stierle DB. (1993) Taxol and taxane production by Taxomycesandreanae, an endophytic fungus of pacific yew. Science, 260: 214- 216.
42. Ge J, Ping W, Zhou D. (2004) Characterization of a new species of taxol-producing fungus. Nature and Science, 2: 85-88.
43. Yuan J, Jian-Nan B, Bing Y, Xu-Dong Z. (2006) Taxol-producing fungi: a new approach to industrial production of taxol. Chinese Journal of Biotechnology, 22: 1-6.

44. Kusari S, Zuhlke S, Spiteller M. (2009) An endophytic fungus from Camptotheca acuminata that produces camptothecin and analogues. Journal of Natural Products, 72:2–7.
45. Touseef A, Musarat A, Sharma PR, Puri SC, Hanan MY, Areej MA, Qazi GN. (2012) Effect of precursors feeding and media manipulation on production of novel anticancer pro-drug camptothecin from endophytic fungus. Brazilian Journal of Microbiology, 43: 1476-1489.
46. Kharwar RN, Verma VC, Strobel G, Ezra D. (2008) The endophytic fungal complex of Catharanthus roseus (L.) G. Don. Current Science, 95: 228–233
47. Eyberger AL, Dondapati R, Porter JR. (2006) Endophyte fungal isolates from Podophyllum peltatum produces podophyllotoxin. Journal of Natural Products, 69:1121-1124.
48. Luqmani, Y.A. Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract, 2005; 14: 35–48. [Google Scholar] [CrossRef]
49. Wu, Q.; Yang, Z.; Nie, Y.; Shi, Y.; Fan, D. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett, 2014; 347: 159–166. [Google Scholar] [CrossRef] [PubMed]
50. Wang, J.; Seebacher, N.; Shi, H.; Kan, Q.; Duan, Z. Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget, 2017; 8: 84559–84571. [Google Scholar] [CrossRef] [PubMed][Green Version]
51. Wang, X.; Zhang, H.; Chen, X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist, 2019; 2: 141–160. [Google Scholar] [CrossRef][Green Version]
52. Dallavalle, S.; Dobričić, V.; Lazzarato, L.; Gazzano, E.; Machuqueiro, M.; Pajeva, I.; Tsakovska, I.; Zidar, N.; Fruttero, R. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist. Updat, 2020; 50: 100682. [Google Scholar] [CrossRef]
53. britannica.com/science/anticancer-drug.